HALOZYME THERAPEUTICS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
HALOZYME THERAPEUTICS, INC. (HALO) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of -$2.69 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-22.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2022-02-22
- HALOZYME THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2021 was -$2.69M.
- HALOZYME THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2020 was -$4.12M, a 1406.98% decline from fiscal 2019.
- HALOZYME THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2019 was $315.00K.
- HALOZYME THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2018 was -$441.00K, a 184.00% decline from fiscal 2017.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month as first filed |
|---|---|---|
| 2021-12-31 | -$2.69M 10-K · filed 2022-02-22 | |
| 2020-12-31 | -$4.12M 10-K · filed 2022-02-22 | |
| 2019-12-31 | $315.00K 10-K · filed 2022-02-22 | |
| 2018-12-31 | -$441.00K 10-K · filed 2021-02-23 | $425.00K 10-K · filed 2019-02-21 |
| 2017-12-31 | $525.00K 10-K · filed 2020-02-24 | |
| 2016-12-31 | $3.73M 10-K · filed 2019-02-21 | |
| 2015-12-31 | -$4.99M 10-K · filed 2018-02-20 | |
| 2014-12-31 | -$529.00K 10-K · filed 2017-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |